

Lorraine Harper

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7824242/publications.pdf>

Version: 2024-02-01

82

papers

6,782

citations

117571

34

h-index

79644

73

g-index

83

all docs

83

docs citations

83

times ranked

4165

citing authors

#	ARTICLE	IF	CITATIONS
1	Decreased renal function is associated with incident dementia: An IMRDâ€THIN retrospective cohort study in the UK. Alzheimer's and Dementia, 2022, , .	0.4	4
2	MO250: COVID-19 Associated Collapsing Variant of Focal Segmental Glomerulosclerosis: A Case Series of 7 Patients from a Single UK Centre. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
3	The Sound of Interconnectivity; The European Vasculitis Society 2022 Report. Kidney International Reports, 2022, 7, 1745-1757.	0.4	3
4	Cardiovascular and Renal Morbidity in Takayasu Arteritis: A Populationâ€Based Retrospective Cohort Study From the United Kingdom. Arthritis and Rheumatology, 2021, 73, 504-511.	2.9	20
5	Predicting relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis: a Systematic review and meta-analysis. Rheumatology Advances in Practice, 2021, 5, rkab018.	0.3	13
6	Latent Cytomegalovirus Infection and Previous Capsular Polysaccharide Vaccination Predict Poor Vaccine Responses in Older Adults, Independent of Chronic Kidney Disease. Clinical Infectious Diseases, 2021, 73, e880-e889.	2.9	6
7	Hemodialysis Patients Make Long-Lived Antibodies against SARS-CoV-2 that May Be Associated with Reduced Reinfection. Journal of the American Society of Nephrology: JASN, 2021, 32, 2140-2142.	3.0	12
8	Reply. Arthritis and Rheumatology, 2021, 73, 1948-1950.	2.9	0
9	Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients. Lancet, The, 2021, 398, 1038-1041.	6.3	73
10	Reply. Arthritis and Rheumatology, 2021, 73, 2145-2146.	2.9	0
11	Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis. Rheumatology Advances in Practice, 2021, 5, rkab039.	0.3	0
12	Management of fatigue with physical activity and behavioural change support in vasculitis: a feasibility study. Rheumatology, 2021, 60, 4130-4140.	0.9	10
13	Addressing the transition to a chronic condition: exploring independent adoption of self-management by patients with ANCA-associated vasculitis. Rheumatology Advances in Practice, 2021, 5, rkab075.	0.3	2
14	Response to â€lgA vasculitis in adults: few certainties and many uncertaintiesâ€™ by HoÃevar et al. Annals of the Rheumatic Diseases, 2020, 79, e48-e48.	0.5	1
15	Response to: â€Mycophenolate mofetil: a step forward in the induction treatment of ANCA-associated vasculitis? Comment on the article by Jones<i>et alâ€™</i> by Vanderghenst<i>et al</i>. Annals of the Rheumatic Diseases, 2020, 79, e101-e101.	0.5	0
16	Response to: â€MYCYC, unravelling the long road ahead in ANCA-associated vasculitisâ€™ by Jain <i>et al</i>. Annals of the Rheumatic Diseases, 2020, 79, e58-e58.	0.5	0
17	Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis. Journal of Rheumatology, 2020, 47, 580-588.	1.0	5
18	The Longitudinal Course of Fatigue in Antineutrophil Cytoplasmic Antibodyâ€associated Vasculitis. Journal of Rheumatology, 2020, 47, 572-579.	1.0	12

#	ARTICLE	IF	CITATIONS
19	Psychological and self-management support for people with vasculitis or connective tissue diseases: UK health professionals' perspectives. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa016.	0.3	1
20	B cell therapies in antineutrophil cytoplasmic antibody-associated vasculitis: why measure B cells and immunoglobulins?. <i>Nephrology Dialysis Transplantation</i> , 2020, , .	0.4	0
21	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1243-1249.	0.5	93
22	Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines-Executive summary. <i>Rheumatology</i> , 2020, 59, 727-731.	0.9	5
23	Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. <i>Rheumatology</i> , 2020, 59, e24-e32.	0.9	42
24	Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2020, 382, 622-631.	13.9	465
25	Subclinical Reactivation of Cytomegalovirus Drives CD4+CD28null T-Cell Expansion and Impaired Immune Response to Pneumococcal Vaccination in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Journal of Infectious Diseases</i> , 2019, 219, 234-244.	1.9	26
26	Podocytes and Proteinuria in ANCA-Associated Glomerulonephritis: A Case-Control Study. <i>Frontiers in Immunology</i> , 2019, 10, 1405.	2.2	9
27	Glucocorticoid induced adrenal insufficiency is common in steroid treated glomerular diseases - proposed strategy for screening and management. <i>BMC Nephrology</i> , 2019, 20, 154.	0.8	18
28	Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review. <i>Autoimmunity Reviews</i> , 2019, 18, 535-541.	2.5	26
29	Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study. <i>BMC Nephrology</i> , 2019, 20, 58.	0.8	64
30	Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases. <i>Rheumatology</i> , 2019, 58, 889-896.	0.9	35
31	Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 399-405.	0.5	165
32	Cardiovascular, thromboembolic and renal outcomes in IgA vasculitis (Henoch-Schönlein purpura): a retrospective cohort study using routinely collected primary care data. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 261-269.	0.5	50
33	Treatment of fatigue with physical activity and behavioural change support in vasculitis: study protocol for an open-label randomised controlled feasibility study. <i>BMJ Open</i> , 2018, 8, e023769.	0.8	14
34	The complications of vasculitis and its treatment. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 125-136.	1.4	13
35	The host cellular immune response to cytomegalovirus targets the endothelium and is associated with increased arterial stiffness in ANCA-associated vasculitis. <i>Arthritis Research and Therapy</i> , 2018, 20, 194.	1.6	20
36	Humoral immunity to memory antigens and pathogens is maintained in patients with chronic kidney disease. <i>PLoS ONE</i> , 2018, 13, e0195730.	1.1	4

#	ARTICLE	IF	CITATIONS
37	How does the outcome of research training fellowships funded via the NHS compare with that from competitively funded fellowships from the MRC and other charities: a cross-sectional retrospective survey of trainees undertaking research training in the West Midlands. <i>BMJ Open</i> , 2018, 8, e019630.	0.8	1
38	Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. <i>Journal of the American Society of Nephrology</i> : JASN, 2017, 28, 2756-2767.	3.0	448
39	Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse. <i>Arthritis Research and Therapy</i> , 2017, 19, 129.	1.6	42
40	The European Vasculitis Society 2016 Meeting Report. <i>Kidney International Reports</i> , 2017, 2, 1018-1031.	0.4	21
41	Avoidance of Harm From Treatment for ANCA-Associated Vasculitis. <i>Current Treatment Options in Rheumatology</i> , 2017, 3, 230-243.	0.6	30
42	Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 338.	0.7	12
43	Physical Fatigue, Fitness, and Muscle Function in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis Care and Research</i> , 2016, 68, 1332-1339.	1.5	19
44	Cardiovascular, muscular and perceptual contributions to physical fatigue in prevalent kidney transplant recipients. <i>Transplant International</i> , 2016, 29, 338-351.	0.8	12
45	Caveolin-1 single-nucleotide polymorphism and arterial stiffness in non-dialysis chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1140-1144.	0.4	10
46	Association of Low B Cell Count and IgG Levels With Infection, and Poor Vaccine Response With All-Cause Mortality in an Immunosuppressed Vasculitis Population. <i>Arthritis Care and Research</i> , 2016, 68, 853-860.	1.5	17
47	Skewed Fc Glycosylation Profiles of Anti-proteinase 3 Immunoglobulin G1 Autoantibodies from Granulomatosis with Polyangiitis Patients Show Low Levels of Bisection, Galactosylation, and Sialylation. <i>Journal of Proteome Research</i> , 2015, 14, 1657-1665.	1.8	49
48	Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2015, 30 Suppl 1, i164-70.	0.4	10
49	CD4+CD28 ^{hi} T-cell expansions in ANCA-associated vasculitis and association with arterial stiffness: baseline data from a randomised controlled trial. <i>Lancet</i> , The, 2015, 385, S30.	6.3	17
50	Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. <i>Rheumatology</i> , 2015, 54, 471-481.	0.9	104
51	Successful outcome of pregnancy in patients with anti-neutrophil cytoplasm antibody-associated small vessel vasculitis. <i>Kidney International</i> , 2015, 87, 807-811.	2.6	23
52	Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 177-184.	0.5	214
53	Endothelial Nitric Oxide Synthase Single Nucleotide Polymorphism and Left Ventricular Function in Early Chronic Kidney Disease. <i>PLoS ONE</i> , 2015, 10, e0116160.	1.1	15
54	BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. <i>Rheumatology</i> , 2014, 53, 2306-2309.	0.9	246

#	ARTICLE	IF	CITATIONS
55	The characterisation and determinants of quality of life in ANCA associated vasculitis. Annals of the Rheumatic Diseases, 2014, 73, 207-211.	0.5	74
56	Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatology, 2014, 53, 953-956.	0.9	38
57	Small vessel vasculitides. Medicine, 2014, 42, 138-145.	0.2	2
58	Explaining fatigue in ANCA-associated vasculitis. Rheumatology, 2013, 52, 1680-1685.	0.9	50
59	Intravenous Cyclophosphamide and Plasmapheresis in Dialysis-Dependent ANCA-Associated Vasculitis. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 219-224.	2.2	49
60	L42. Morbidity in patients with ANCA-associated vasculitis. Presse Medicale, 2013, 42, 612-616.	0.8	9
61	Antineutrophil Cytoplasm Antibody-Associated Vasculitis. , 2013, , 1481-1497.e4.		0
62	Complications of long-term therapy for ANCA-associated systemic vasculitis. Nature Reviews Nephrology, 2012, 8, 523-532.	4.1	49
63	Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Annals of the Rheumatic Diseases, 2012, 71, 955-960.	0.5	348
64	Long-term patient survival in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2011, 70, 488-494.	0.5	719
65	A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care and Research, 2011, 63, 588-596.	1.5	147
66	CD4+CD28 ⁺ T cell expansion in granulomatosis with polyangiitis (Wegener's) is driven by latent cytomegalovirus infection and is associated with an increased risk of infection and mortality. Arthritis and Rheumatism, 2011, 63, 2127-2137.	6.7	56
67	Recent advances to achieve remission induction in antineutrophil cytoplasmic antibody-associated vasculitis. Current Opinion in Rheumatology, 2010, 22, 37-42.	2.0	4
68	ANCA-associated vasculitides-lessons from the adult literature. Pediatric Nephrology, 2010, 25, 1397-1407.	0.9	7
69	Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. JAMA - Journal of the American Medical Association, 2010, 304, 2381.	3.8	524
70	Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Annals of the Rheumatic Diseases, 2010, 69, 1036-1043.	0.5	344
71	Adverse effects of therapy for ANCA-associated vasculitis. Best Practice and Research in Clinical Rheumatology, 2009, 23, 391-401.	1.4	46
72	Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: A matched-pair cohort study. Arthritis and Rheumatism, 2009, 60, 3493-3500.	6.7	110

#	ARTICLE	IF	CITATIONS
73	Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Annals of Internal Medicine</i> , 2009, 150, 670.	2.0	790
74	ANCA-associated vasculitis: new options beyond steroids and cytotoxic drugs. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 689-703.	1.9	11
75	Recurrences and Infections During Continuous Immunosuppressive Therapy After Beginning Dialysis in ANCA-Associated Vasculitis. <i>American Journal of Kidney Diseases</i> , 2007, 50, 36-46.	2.1	59
76	Anti-Neutrophil Cytoplasm-Associated Glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1224-1234.	3.0	105
77	ANCA-associated vasculitis: is there a role for neutrophil apoptosis in autoimmunity?. <i>Expert Review of Clinical Immunology</i> , 2006, 2, 237-244.	1.3	3
78	Prospective Study of TNF Blockade with Infliximab in Anti-Neutrophil Cytoplasmic Antibody-Associated Systemic Vasculitis. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 717-721.	3.0	345
79	Dendritic cell uptake of human apoptotic and necrotic neutrophils inhibits CD40, CD80, and CD86 expression and reduces allogeneic T cell responses: Relevance to systemic vasculitis. <i>Arthritis and Rheumatism</i> , 2003, 48, 2362-2374.	6.7	71
80	New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis. <i>Current Opinion in Rheumatology</i> , 2002, 14, 15-22.	2.0	70
81	Neutrophil priming and apoptosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis1. <i>Kidney International</i> , 2001, 59, 1729-1738.	2.6	148
82	Antineutrophil Cytoplasmic Antibodies Induce Reactive Oxygen-Dependent Dysregulation of Primed Neutrophil Apoptosis and Clearance by Macrophages. <i>American Journal of Pathology</i> , 2000, 157, 211-220.	1.9	101